Key result
The ADRB1 Arg389Arg and ADRA2C deletion carrier genotype combination was associated with a significantly higher final ejection fraction in heart failure patients treated with metoprolol.
Why the study?
Do ADRB1 and ADRA2C polymorphisms synergistically influence the ejection fraction response to metoprolol therapy in beta-blocker naive heart failure patients?
Cohort (n=54)
Do ADRB1 and ADRA2C polymorphisms synergistically influence the ejection fraction response to metoprolol therapy in beta-blocker naive heart failure patients?
Answers are grounded in this paper and cite their sources.
The combination of ADRB1 Arg389Arg and ADRA2C deletion carrier genotypes predicts a significantly greater improvement in left ventricular ejection fraction in heart failure patients treated with metoprolol.
OBJECTIVES: The Arg389Gly polymorphism (Arg389Gly) in the beta1-adrenergic receptor gene (ADRB1) has been associated with improvement in left-ventricular remodeling with beta-blocker treatment. One study of risk for heart failure suggested a synergistic effect of ADRB1 Arg389Gly with the insertion/deletion polymorphism in the alpha2C-adrenergic receptor gene (ADRA2C). We tested whether the ADRA2C insertion/deletion polymorphism was associated with beta-blocker response in heart failure, either alone or in combination with the ADRB1Arg389Gly polymorphism. METHODS: Fifty-four beta-blocker naive heart failure patients underwent echocardiography before and after 5-6 months of metoprolol CR/XL therapy. Multivariant linear regression modeling was performed to assess the impact of genotypes and other variables on changes in left-ventricular function in response to metoprolol therapy. RESULTS: Deletion carriers had a significantly greater negative chronotropic response. Predictors of the end of study ejection fraction were baseline ejection fraction, deletion carrier status and Arg389Arg genotype. Patients with Arg389Arg/Del-carrier status showed the greatest ejection fraction increase with metoprolol CR/XL. Adjusting for baseline ejection fraction, final S-metoprolol plasma concentration and race, final ejection fraction in patients with this genotype combination was significantly higher than all other genotype combination groups. CONCLUSION: ADRB1 and ADRA2C polymorphisms synergistically influence the ejection fraction response to beta-blocker therapy of heart failure patients.
No takes yet. Share an insight, caveat, or question.
Lobmeyer et al. (2007) conducted a cohort in heart failure (n=54). ADRB1 Arg389Arg and ADRA2C deletion carrier genotypes vs. Other genotype combinations was evaluated on change in left-ventricular ejection fraction. The ADRB1 Arg389Arg and ADRA2C deletion carrier genotype combination was associated with a significantly higher final ejection fraction in heart failure patients treated with metoprolol.
Synapse has enriched 10 related papers. Consider them for comparative context: